Molecular structure of VU0155069, CAS Number: 1130067-06-9
VU0155069 (CAS 1130067-06-9)
See product citations (7)
Alternate Names:
N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-naphthalenecarboxamide
Application:
VU0155069 is a potent and specific inhibitor of phospholipase D1
CAS Number:
1130067-06-9
Purity:
≥95%
Molecular Weight:
462.98
Molecular Formula:
C26H27ClN4O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
VU0155069 is a potent and specific inhibitor of PC-PLD1 (phospholipase D1). VU0155069 significantly decreases invasive migration in breast cancer cell lines (MDA-231, 4T1 and PMT). VU0155069 is an inhibitor of PC-PLD2.
VU0155069 (CAS 1130067-06-9) References
- Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. | Scott, SA., et al. 2009. Nat Chem Biol. 5: 108-17. PMID: 19136975
- Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. | Tsai, YR., et al. 2013. Naunyn Schmiedebergs Arch Pharmacol. 386: 507-19. PMID: 23525454
- Phospholipase D1 has a pivotal role in interleukin-1β-driven chronic autoimmune arthritis through regulation of NF-κB, hypoxia-inducible factor 1α, and FoxO3a. | Kang, DW., et al. 2013. Mol Cell Biol. 33: 2760-72. PMID: 23689131
- The influence of polyunsaturated fatty acids on the phospholipase D isoforms trafficking and activity in mast cells. | Basiouni, S., et al. 2013. Int J Mol Sci. 14: 9005-17. PMID: 23698760
- Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells. | Kang, DW., et al. 2017. Cancer Res. 77: 142-152. PMID: 27793841
- PLD1 regulates adipogenic differentiation through mTOR - IRS-1 phosphorylation at serine 636/639. | Song, HI. and Yoon, MS. 2016. Sci Rep. 6: 36968. PMID: 27872488
- Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer. | Cheng, M., et al. 2017. Neoplasia. 19: 617-627. PMID: 28654865
- Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits. | Krishnan, B., et al. 2018. Alzheimers Dement (N Y). 4: 89-102. PMID: 29560412
- Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. | Skafi, N., et al. 2019. J Cell Physiol. 234: 4825-4839. PMID: 30207376
- Role of phospholipase D in migration and invasion induced by linoleic acid in breast cancer cells. | Diaz-Aragon, R., et al. 2019. Mol Cell Biochem. 457: 119-132. PMID: 30877512
- PLD1 promotes dendritic spine morphogenesis via activating PKD1. | Li, WQ., et al. 2019. Mol Cell Neurosci. 99: 103394. PMID: 31356881
- VU0155069 inhibits inflammasome activation independent of phospholipase D1 activity. | Lee, SK., et al. 2019. Sci Rep. 9: 14349. PMID: 31586128
- Phospholipase D and phosphatidylinositol-4-phosphate 5-kinase 1 are involved in the regulation of oligodendrocyte morphological differentiation. | Kato, Y., et al. 2021. Exp Cell Res. 405: 112654. PMID: 34044015
- Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer. | Hwang, WC., et al. 2022. Exp Mol Med. 54: 1563-1576. PMID: 36131027
- Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease. | Wang, H., et al. 2023. JHEP Rep. 5: 100726. PMID: 37138676
Inhibitor of:
PC-PLD1, and PC-PLD2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VU0155069, 1 mg | sc-224371 | 1 mg | $70.00 | |||
VU0155069, 5 mg | sc-224371A | 5 mg | $173.00 | |||
VU0155069, 10 mg | sc-224371B | 10 mg | $291.00 | |||
VU0155069, 25 mg | sc-224371C | 25 mg | $510.00 |